Skip to search formSkip to main contentSkip to account menu

drozitumab

Known as: Anti-DR5 Monoclonal Antibody, Immunoglobulin G1, anti-(human tumor necrosis factor receptor superfamily member 10B (death receptor 5, TRAIL-R2, CD262 antigen)); [113-lysine,116-threonine,360-glutamic acid,362-methionine]human monoclonal gamma-1 heavy chain (224-212')-disulfide with human monoclonal lambda-3 light chain (230-230'':233-233'')-bisdisulfide dimer, rhuMAb DR5 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (1)

Monoclonal Antibodies

Narrower (1)

PRO 95780
antigen binding

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Development of a bioassay as a measure of drozitumab-mediated apoptosis induced by soluble Fc gamma receptors.
Review
2015
Review
2015
New Frontiers in Promoting TRAIL-Mediated Cell Death: Focus on Natural Sensitizers, miRNAs, and Nanotechnological Advancements
Cancer is a multifaceted and genomically complex disease, and rapidly emerging scientific evidence is emphasizing on intra-tumor… 
2015
2015
Abstract P5-10-05: TRAIL receptor agonists target basal B triple negative breast Cancer (TNBC) that expresses vimentin and axl
Background: Tumor Necrosis Factor Related Ligand (TRAIL) triggers apoptosis by binding to cell surface receptors. We previously… 
2014
2014
Abstract LB-113: A novel role of Withaferin A as an effective pro-apoptotic receptor agonist (PARA) and insights into the underlying molecular mechanisms
Introduction: Despite significant progress towards screening efforts and targeted therapies, breast cancer is still a leading… 
2012
2012
Activating Death Receptor DR5 as a Therapeutic Strategy for Rhabdomyosarcoma
Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children. It is believed to arise from skeletal muscle… 
2012
2012
Abstract 3856: Dimerized single chain TRAIL-receptor agonists do not depend on Fc-gamma-receptor cross-linking for anti-tumor efficacyin vivo
APG350 is a TRAIL-receptor (TRAIL-R) agonist comprising two single-chain TRAIL-R binding domains (scTRAIL-RBD) that are dimerized… 
2012
2012
Abstract 254: Genome-wide shRNA screening identifies candidate proteins modulating the extrinsic apoptotic pathway
Apoptosis is a highly regulated process critical for embryonic development, and tissue and organ homeostasis. Deregulation of… 
2011
2011
Phase Ib study of drozitumab combined with first-line FOLFOX plus bevacizumab (BV) in patients (pts) with metastatic colorectal cancer (mCRC).
546 Background: Drozitumab is a monoclonal antibody that triggers tumor cell apoptosis by selective agonistic interaction with… 
2011
2011
Phase Ib study of dulanermin combined with first-line FOLFOX plus bevacizumab (BV) in patients (Pts) with metastatic colorectal cancer (mCRC).
546 Background: Drozitumab is a monoclonal antibody that triggers tumor cell apoptosis by selective agonistic interaction with… 
2011
2011
Phase Ib study of drozitumab combined with cetuximab (CET) plus irinotecan (IRI) or with FOLFIRI with or without bevacizumab (BV) in previously treated patients (pts) with metastatic colorectal…
532 Background: Drozitumab is a monoclonal antibody that triggers tumor cell apoptosis by selective agonistic interaction with… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)